1. Carnitine

   Case report 17 February 2024 Pages: 51 - 51

2. Caspofungin/fluconazole

   Case report 17 February 2024 Pages: 52 - 52

3. Cefepime

   Case report 17 February 2024 Pages: 53 - 53

4. Certolizumab pegol/Golimumab/Secukinumab

   Case report 17 February 2024 Pages: 54 - 54

5. Cetirizine/montelukast

   Case report 17 February 2024 Pages: 55 - 55

6. Ciprofloxacin/colchicine

   Case report 17 February 2024 Pages: 56 - 56

7. Cisplatin

   Case report 17 February 2024 Pages: 57 - 57

8. Cisplatin/Gemcitabine

   Case report 17 February 2024 Pages: 58 - 58

9. Clonidine/Nifedipine/Olmesartan-medoxomil overdose

   Case report 17 February 2024 Pages: 59 - 59

10. Clozapine/paliperidone/pipotiazine

    Case report 17 February 2024 Pages: 60 - 60

11. Convalescent-anti-SARS-CoV-2-plasma/corticosteroids/remdesivir

    Case report 17 February 2024 Pages: 61 - 61

12. Cyclophosphamide

    Case report 17 February 2024 Pages: 62 - 62

13. Cyclophosphamide/Doxorubicin/Paclitaxel

    Case report 17 February 2024 Pages: 63 - 63

14. Cyclophosphamide/Prednisolone/Tacrolimus

    Case report 17 February 2024 Pages: 64 - 64

15. Dalbavancin/daptomycin/linezolid

    Case report 17 February 2024 Pages: 65 - 65

16. Dapagliflozin

    Case report 17 February 2024 Pages: 66 - 66

17. Dapsone

    Case report 17 February 2024 Pages: 67 - 67

18. Dapsone

    Case report 17 February 2024 Pages: 68 - 68

19. Deferoxamine

    Case report 17 February 2024 Pages: 69 - 69

20. Dexamethasone/eltrombopag/immune globulin

    Case report 17 February 2024 Pages: 70 - 70

21. Dexamethasone/Methylprednisolone/Posaconazole

    Case report 17 February 2024 Pages: 71 - 71

22. Docetaxel

    Case report 17 February 2024 Pages: 72 - 72

23. Docetaxel/gemcitabine/toripalimab

    Case report 17 February 2024 Pages: 73 - 73

24. Dofetilide/nadolol

    Case report 17 February 2024 Pages: 74 - 74

25. Doxorubicin/ifosfamide

    Case report 17 February 2024 Pages: 75 - 75

26. Doxycycline

    Case report 17 February 2024 Pages: 76 - 76

27. Dronedarone

    Case report 17 February 2024 Pages: 77 - 77

28. Dupilumab

    Case report 17 February 2024 Pages: 78 - 78

29. Elasomeran

    Case report 17 February 2024 Pages: 79 - 79

30. Enoxaparin-sodium/Heparin/Warfarin

    Case report 17 February 2024 Pages: 80 - 80

31. Enoxaparin-sodium/Urokinase

    Case report 17 February 2024 Pages: 81 - 81

32. Eravacycline

    Case report 17 February 2024 Pages: 82 - 82

33. Ferrous-gluconate/ferrous-sulfate

    Case report 17 February 2024 Pages: 83 - 83

34. Flecainide/propafenone

    Case report 17 February 2024 Pages: 84 - 84

35. Gefitinib/Osimertinib

    Case report 17 February 2024 Pages: 85 - 85

36. Glipizide/metformin/nivolumab

    Case report 17 February 2024 Pages: 86 - 86

37. Hydroxycarbamide

    Case report 17 February 2024 Pages: 87 - 87

38. Hydroxychloroquine/infliximab

    Case report 17 February 2024 Pages: 88 - 88

39. Ibrutinib

    Case report 17 February 2024 Pages: 89 - 89

40. Ibrutinib

    Case report 17 February 2024 Pages: 90 - 90

41. Immune-globulin

    Case report 17 February 2024 Pages: 91 - 91

42. Immune-globulin/methylprednisolone/rituximab

    Case report 17 February 2024 Pages: 92 - 92

43. Immunosuppressants

    Case report 17 February 2024 Pages: 93 - 93

44. Immunosuppressants

    Case report 17 February 2024 Pages: 94 - 94

45. Immunotherapies

    Case report 17 February 2024 Pages: 95 - 95

46. Infliximab

    Case report 17 February 2024 Pages: 96 - 96

47. Infliximab/Ustekinumab

    Case report 17 February 2024 Pages: 97 - 97

48. Iodine-radioactive/recombinant-human-thyroid-stimulating-hormone-Suzhou-Zelgen-Biopharmaceuticals

    Case report 17 February 2024 Pages: 98 - 98

49. Ipilimumab/nivolumab

    Case report 17 February 2024 Pages: 99 - 99

50. Ipilimumab/nivolumab/pembrolizumab

    Case report 17 February 2024 Pages: 100 - 100